AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30224341 — intervention group
Group type: COMPARATOR
Intervention: High plasma VEGF-A levels (>5.1 pg/mL)
Number of subjects: 376
Study 27939574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg capsule orally, 1 hour before surgery and 75 mg twice a day for 2 days postoperatively)
Number of subjects: 71
Study 27939574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 71
Study 27939574 — intervention group
Group type: COMPARATOR
Intervention: Control (2 similar-looking multivitamin capsules)
Number of subjects: 71
Study 27939574 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 71
Study 25879524 — intervention group
Group type: EXPERIMENTAL
Intervention: olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ)
Number of subjects: 2690
Study 22554293 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% alendronate gel
Number of subjects: 69
Study 22554293 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 69
Study 21317170 — intervention group
Group type: COMPARATOR
Intervention: teduglutide 0.10 mg/kg/day
Number of subjects: 83
Study 21317170 — intervention group
Group type: COMPARATOR
Intervention: teduglutide 0.05 mg/kg/day
Number of subjects: 83
Study 21317170 — intervention group
Group type: COMPARATOR
Intervention: teduglutide (both doses)
Number of subjects: 83
Study 21317170 — intervention group
Group type: COMPARATOR
Intervention: teduglutide
Number of subjects: 83
Study 19592279 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of depressive symptoms
Number of subjects: 572
Study 19592279 — intervention group
Group type: COMPARATOR
Intervention: Locus of control
Number of subjects: 572
Study 18705947 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose human albumin (2 g/kg) administered in a 2-hour intravenous infusion within 5 hours of symptom onset
Number of subjects: 1800
Study 18705947 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 1800
Study 18705947 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose human albumin (2 g/kg)
Number of subjects: 1800
Study 15499139 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetic rebreathing circuit
Number of subjects: 24
Study 15499139 — intervention group
Group type: COMPARATOR
Intervention: Ventilator with volume guarantee
Number of subjects: 24
Study 11451176 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment (daily dose of interferon) with ribavirin 1,000-1,200 mg
Number of subjects: 244
Study 11451176 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (interferon thrice weekly) with ribavirin 1,000-1,200 mg
Number of subjects: 244
Study 9592045 — intervention group
Group type: EXPERIMENTAL
Intervention: GDNF
Number of subjects: 0
Study 9592045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ret
Number of subjects: 0
Study 8152279 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0
Study 8152279 — intervention group
Group type: COMPARATOR
Intervention: Interferon (IFN) based treatment regimens
Number of subjects: 0
Study 8152279 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy or IFN-monotherapy
Number of subjects: 0
Study 3043692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil
Number of subjects: 64
Study 3043692 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 64
Study 29680338 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD Consortium clinical score (CAD2)
Number of subjects: 1738
Study 29680338 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated Diamond-Forrester score (UDF)
Number of subjects: 1738
Study 29680338 — intervention group
Group type: EXPERIMENTAL
Intervention: CONFIRM risk score (CRS)
Number of subjects: 1738
Study 27925849 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric emergency ruler (PaedER)
Number of subjects: 150
Study 27547925 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor fecal microbiota transplantation (FMT) administered by colonoscopy
Number of subjects: 46
Study 27547925 — intervention group
Group type: COMPARATOR
Intervention: Autologous fecal microbiota transplantation (FMT) administered by colonoscopy
Number of subjects: 46
Study 27547925 — intervention group
Group type: COMPARATOR
Intervention: Autologous FMT by site
Number of subjects: 46
Study 24150784 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute passive vibration (PV) at 25 Hz and 2 mm amplitude
Number of subjects: 11
Study 24150784 — intervention group
Group type: COMPARATOR
Intervention: Control (no-PV)
Number of subjects: 11
Study 24150784 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute passive vibration (PV)
Number of subjects: 11
Study 22716974 — intervention group
Group type: EXPERIMENTAL
Intervention: Midurethral sling
Number of subjects: 337
Study 22716974 — intervention group
Group type: COMPARATOR
Intervention: Sham incisions
Number of subjects: 337
Study 19342023 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH plus finasteride
Number of subjects: 36
Study 19342023 — intervention group
Group type: COMPARATOR
Intervention: rFSH alone
Number of subjects: 36
Study 17355994 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored advice on strength and balance training (SBT) activities, n = 144
Number of subjects: 280
Study 17355994 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving all advice without tailoring, n = 136
Number of subjects: 280
Study 16373948 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg breakfast
Number of subjects: 30
Study 11921013 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality treatment for limited stage Hodgkin's lymphoma
Number of subjects: 0
Study 11921013 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD regimen
Number of subjects: 0
Study 11921013 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation
Number of subjects: 0
Study 11921013 — intervention group
Group type: EXPERIMENTAL
Intervention: Future studies
Number of subjects: 0
Study 10663896 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofragmentable anastomosis ring (BAR)
Number of subjects: 36
Study 10663896 — intervention group
Group type: COMPARATOR
Intervention: Stapled anastomosis
Number of subjects: 36
Study 7571984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of AT III (two different dosages)
Number of subjects: 50
Study 7571984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2193613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 547
Study 2193613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study 389148 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG feedback therapy
Number of subjects: 28
Study 30916742 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus Extensive Intraoperative Peritoneal Lavage (EIPL)
Number of subjects: 662
Study 30916742 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 662
Study 30360531 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative paravertebral block (PVB) with bupivacaine
Number of subjects: 90
Study 30360531 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative paravertebral block (PVB) with bupivacaine
Number of subjects: 90
Study 30360531 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PVB)
Number of subjects: 90
Study 26661685 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra virgin coconut oil (EVCO)
Number of subjects: 148
Study 26661685 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil (EVOO)
Number of subjects: 148
Study 26661685 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice bran oil (RBO)
Number of subjects: 148
Study 26661685 — intervention group
Group type: COMPARATOR
Intervention: Butter (control)
Number of subjects: 148
Study 26661685 — intervention group
Group type: EXPERIMENTAL
Intervention: Health benefit statement for oils
Number of subjects: 148
Study 24767009 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based trauma-focused cognitive behavioural therapy with exposure components
Number of subjects: 125
Study 24767009 — intervention group
Group type: COMPARATOR
Intervention: Internet-based trauma-focused cognitive behavioural therapy without exposure components
Number of subjects: 125
Study 23132187 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 64
Study 23132187 — intervention group
Group type: COMPARATOR
Intervention: Reading control condition
Number of subjects: 64
Study 20708444 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 69
Study 20708444 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 69
Study 20708444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 17403002 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical therapy (IMT)
Number of subjects: 100
Study 17403002 — intervention group
Group type: EXPERIMENTAL
Intervention: IMT (with or without psychological interventions)
Number of subjects: 100
Study 17403002 — intervention group
Group type: EXPERIMENTAL
Intervention: IMT plus psychological interventions (IMT-MR or IMT-CBT)
Number of subjects: 100
Study 17403002 — intervention group
Group type: EXPERIMENTAL
Intervention: IMT-CBT
Number of subjects: 100
Study 17403002 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 100
Study 17998645 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy with or without chemotherapy
Number of subjects: 178
Study 17476649 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological interventions (specific details not provided)
Number of subjects: 0
Study 17476649 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental variable (IV) methods for estimation
Number of subjects: 0
Study 17476649 — intervention group
Group type: EXPERIMENTAL
Intervention: Three two-stage estimation procedures
Number of subjects: 0
Study 10627102 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-service sales of beer, wine, and spirits
Number of subjects: 14
Study 10627102 — intervention group
Group type: COMPARATOR
Intervention: Over-the-counter sales
Number of subjects: 14
Study 8791966 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg b.d.
Number of subjects: 772
Study 8791966 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg q.d.s.
Number of subjects: 772
Study 1537516 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentils (premeal)
Number of subjects: 17
Study 1537516 — intervention group
Group type: COMPARATOR
Intervention: Bread (premeal)
Number of subjects: 17
Study 6332454 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS scopolamine (5 micrograms/h)
Number of subjects: 16
Study 6332454 — intervention group
Group type: EXPERIMENTAL
Intervention: dimenhydrinate (100 mg)
Number of subjects: 16
Study 6332454 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study 30954338 — intervention group
Group type: EXPERIMENTAL
Intervention: IV and topical tranexamic acid (TXA)
Number of subjects: 57
Study 30954338 — intervention group
Group type: COMPARATOR
Intervention: IV tranexamic acid (TXA)
Number of subjects: 57
Study 29638090 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncovered self‐expanding metal stents (SEMS)
Number of subjects: 40
Study 29638090 — intervention group
Group type: COMPARATOR
Intervention: Plastic biliary stents
Number of subjects: 40
Study 26616409 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (3 mg/kg/twice a day of zinc sulfate monohydrate orally for 10 days)
Number of subjects: 0
Study 26616409 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic treatment without zinc (Control)
Number of subjects: 0
Study 23625127 — intervention group
Group type: EXPERIMENTAL
Intervention: SystemCHANGE™‐HIV intervention
Number of subjects: 0
Study 22702146 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal anesthesia (2nd group)
Number of subjects: 61
Study 22702146 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural anesthesia (3rd group)
Number of subjects: 61
Study 22702146 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal‐epidural anesthesia (4th group)
Number of subjects: 61
Study 22702146 — intervention group
Group type: COMPARATOR
Intervention: Traditional endotracheal anesthesia (1st group)
Number of subjects: 61
Study 20522733 — intervention group
Group type: COMPARATOR
Intervention: High-dose EPO (30,000 IU/day for 3 days)
Number of subjects: 15
Study 20522733 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose EPO (5,000 IU/week for 3 months)
Number of subjects: 15
Study 18972289 — intervention group
Group type: EXPERIMENTAL
Intervention: MF‐DPI 400 microg QD PM (1 inhalation)
Number of subjects: 668
Study 18972289 — intervention group
Group type: EXPERIMENTAL
Intervention: MF‐DPI 200 microg BID
Number of subjects: 668
Study 18972289 — intervention group
Group type: EXPERIMENTAL
Intervention: MF‐DPI 200 microg QD PM
Number of subjects: 668
Study 18972289 — intervention group
Group type: EXPERIMENTAL
Intervention: MF‐DPI 400 microg QD PM (2 inhalations of 200 microg)
Number of subjects: 668
Study 18972289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 668
Study 15906422 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg (single oral dose)
Number of subjects: 24
Study 12716810 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine at dinnertime
Number of subjects: 51
Study 12716810 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine at bedtime
Number of subjects: 51
Study 12716810 — intervention group
Group type: COMPARATOR
Intervention: NPH four times/day
Number of subjects: 51
Study 10380726 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised outpatient group training programme (n = 50)
Number of subjects: 101
Study 10380726 — intervention group
Group type: COMPARATOR
Intervention: Standardized recommendations of walking (Control group, n = 51)
Number of subjects: 101
Study 8970345 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 micrograms
Number of subjects: 95
Study 8970345 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 micrograms
Number of subjects: 95
Study 8970345 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 micrograms
Number of subjects: 95
Study 8970345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 1944944 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg/day)
Number of subjects: 30
Study 1944944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31511031 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutropin (0.24 mg/kg/week, 6 times/week)
Number of subjects: 34
Study 31511031 — intervention group
Group type: COMPARATOR
Intervention: Comparator (Genotropin, 0.24 mg/kg/week, 6 times/week)
Number of subjects: 34
Study 28824042 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin 20 mg
Number of subjects: 30
Study 28824042 — intervention group
Group type: COMPARATOR
Intervention: Ipragliflozin 50 mg
Number of subjects: 30
Study 26124793 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia at L5, S1 interspace
Number of subjects: 32
Study 26124793 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia at L3, 4 interspace (Control)
Number of subjects: 32
Study 24100777 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based program supplemented with mobile phone messages (SMS)
Number of subjects: 3855
Study 21859972 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine 1200 mg
Number of subjects: 2308
Study 21859972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2308
Study 19760932 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy (amoxicillin, tetracycline, and metronidazole) for 2 weeks
Number of subjects: 26
Study 19760932 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy
Number of subjects: 26
Study 19760932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 17951228 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQL) measures
Number of subjects: 0
Study 17951228 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs)
Number of subjects: 0
Study 17951228 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trials
Number of subjects: 0
Study 15220014 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline 25 mg IV q12h for 7 to 14 days
Number of subjects: 160
Study 15220014 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline 50 mg IV q12h for 7 to 14 days
Number of subjects: 160
Study 11527456 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization with movement (MWM)
Number of subjects: 25
Study 9692587 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 1.5 mg/kg
Number of subjects: 100
Study 9692587 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 1.5 mg/kg with 1 in 200000 adrenaline
Number of subjects: 100
Study 9692587 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 3 mg/kg
Number of subjects: 100
Study 9692587 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 100
Study 7832183 — intervention group
Group type: EXPERIMENTAL
Intervention: Node-link mapping counseling
Number of subjects: 108
Study 7832183 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 108
Study 7832183 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling with mapping
Number of subjects: 108
Study 7832183 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling
Number of subjects: 108
Study 2971321 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine (0.1%)
Number of subjects: 40
Study 2971321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30386984 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 446
Study 30386984 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 446
Study 28806225 — intervention group
Group type: EXPERIMENTAL
Intervention: Locked procedure pack
Number of subjects: 20
Study 28806225 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 20
Study 25561577 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC)
Number of subjects: 11
Study 25561577 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention (PBO)
Number of subjects: 11
Study 23428340 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative reconstruction (iDose4) with 80 kVp
Number of subjects: 80
Study 23428340 — intervention group
Group type: COMPARATOR
Intervention: Standard dose filtered back projection (FBP) with 120 kVp
Number of subjects: 80
Study 23428340 — intervention group
Group type: COMPARATOR
Intervention: Standard dose filtered back projection (FBP) with 80 kVp
Number of subjects: 80
Study 20233843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 10
Study 20233843 — intervention group
Group type: COMPARATOR
Intervention: Active Recovery (ACT)
Number of subjects: 10
Study 19772452 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 U‐eq capsule (2.6 mg of insulin)
Number of subjects: 59
Study 19772452 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 U‐eq capsule (3.9 mg)
Number of subjects: 59
Study 19772452 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 U‐eq plus two 2 U‐eq capsules (4.4 mg total)
Number of subjects: 59
Study 19772452 — intervention group
Group type: EXPERIMENTAL
Intervention: two 10 U‐eq capsules (7.8 mg total)
Number of subjects: 59
Study 17028486 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 17028486 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 15471390 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term morphine-clofelin epidural analgesia and nitroglycerin infusion
Number of subjects: 90
Study 15471390 — intervention group
Group type: COMPARATOR
Intervention: Conventional intravenous morphine
Number of subjects: 90
Study 11504259 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium sulfate pellets plus decompression bone
Number of subjects: 40
Study 11504259 — intervention group
Group type: COMPARATOR
Intervention: Autologous posterior iliac crest bone
Number of subjects: 40
Study 9257203 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide 0.7 mg/kg
Number of subjects: 45
Study 9257203 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide 0.9 mg/kg
Number of subjects: 45
Study 9257203 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.5 mg/kg
Number of subjects: 45
Study 8491065 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate
Number of subjects: 26
Study 8491065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 3320932 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle wiped with sterile gauze before injection (Group 2)
Number of subjects: 200
Study 3320932 — intervention group
Group type: EXPERIMENTAL
Intervention: Same needle used to draw up and inject (Group 3)
Number of subjects: 200
Study 3320932 — intervention group
Group type: COMPARATOR
Intervention: Needle changed before injection (Group 1)
Number of subjects: 200
Study 31180480 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pregabalin during the perioperative period
Number of subjects: 6
Study 31180480 — intervention group
Group type: COMPARATOR
Intervention: Routine analgesia (Control)
Number of subjects: 6
Study 31180480 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 6
Study 28716168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with house-dust mite extract
Number of subjects: 48
Study 28716168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 26076938 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine, 1 mg daily (n=98)
Number of subjects: 197
Study 26076938 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=99)
Number of subjects: 197
Study 26076938 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 197
Study 26076938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197